Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance.
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
GSK awarded contract by BARDA to support research on potential novel antibiotic
- Details
- Category: GlaxoSmithKline
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
Bayer Confident in Results of ROCKET AF Study
- Details
- Category: Bayer
A Cardiovascular and Renal Drugs Advisory Committee meeting has been scheduled for September 8, 2011, to review the New Drug Application in the USA for rivaroxaban in the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe.
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
- Details
- Category: Novartis
Novartis announced today that the European Commission has approved Afinitor® (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease[3].
AstraZeneca announces top-line results from SATURN study
- Details
- Category: AstraZeneca
AstraZeneca today announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.
More Pharma News ...
- Bayer Healthcare to acquire Pathway Medical Technologies
- Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative
- €1 Million Awarded to Winning Projects
- Additional Analyses from PLATO Presented at ESC Congress
- U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib)
- Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
- Novo Nordisk to build new corporate centre in Bagsværd, Denmark